Clinical Trial Update: Lead-212 PSV359 Therapy for Patients With Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Perspective Therapeutics reports that Lead-212 PSV359 Therapy is being studied in Phase 1/2 trials for multiple solid tumors and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Esophageal Cancer
• Gastric Cancer
• Head and Neck Cancer
• Mesothelioma
• Ovarian Cancer
• Pancreatic Ductal Adenocarcinoma
• Sarcoma

Drugs mentioned

• PSV359 Therapy (Lead-212 PSV359)

Snippet

Sponsor: Perspective Therapeutics | Conditions: Pancreatic Ductal Adenocarcinoma, Gastric Cancer | Phase 1, Phase 2 | Status: RECRUITING